Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Alzheimer's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 136 articles:
HTML format
Text format



Single Articles


    August 2018
  1. PETERSEN RC
    How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture.
    Neurology. 2018 Aug 8. pii: WNL.0000000000006088.
    PubMed     Text format     Abstract available


  2. ASCHENBRENNER AJ, Gordon BA, Benzinger TLS, Morris JC, et al
    Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease.
    Neurology. 2018 Aug 1. pii: WNL.0000000000006075.
    PubMed     Text format     Abstract available


    July 2018

  3. Age-dependent white matter inflammation and cognitive impairment in the TgAPP21 rat model of Alzheimer disease.
    Neurology. 2018;91:242.
    PubMed     Text format    


  4. JANELIDZE S, Mattsson N, Stomrud E, Lindberg O, et al
    CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.
    Neurology. 2018 Jul 27. pii: WNL.0000000000006082.
    PubMed     Text format     Abstract available


  5. JANG H, Bae JB, Dardiotis E, Scarmeas N, et al
    Differential effects of completed and incomplete pregnancies on the risk of Alzheimer disease.
    Neurology. 2018 Jul 18. pii: WNL.0000000000006000.
    PubMed     Text format     Abstract available


  6. ARVANITAKIS Z, Capuano AW, Lamar M, Shah RC, et al
    Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2018 Jul 11. pii: WNL.0000000000005951.
    PubMed     Text format     Abstract available


    June 2018
  7. STRAIN JF, Smith RX, Beaumont H, Roe CM, et al
    Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions.
    Neurology. 2018 Jun 29. pii: WNL.0000000000005864.
    PubMed     Text format     Abstract available


  8. MERLUZZI AP, Carlsson CM, Johnson SC, Schindler SE, et al
    Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.
    Neurology. 2018 Jun 29. pii: WNL.0000000000005901.
    PubMed     Text format     Abstract available


  9. BENARROCH EE
    Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms.
    Neurology. 2018 Jun 13. pii: WNL.0000000000005807.
    PubMed     Text format    


    April 2018
  10. PASSAMONTI L, Rodriguez PV, Hong YT, Allinson KSJ, et al
    [(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy.
    Neurology. 2018 Apr 27. pii: WNL.0000000000005610.
    PubMed     Text format     Abstract available


  11. CUMMINGS JL, Cohen S, van Dyck CH, Brody M, et al
    ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005550.
    PubMed     Text format     Abstract available


  12. BERTI V, Walters M, Sterling J, Quinn CG, et al
    Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults.
    Neurology. 2018 Apr 13. pii: WNL.0000000000005527.
    PubMed     Text format     Abstract available


  13. KERN S, Zetterberg H, Kern J, Zettergren A, et al
    Prevalence of preclinical Alzheimer disease: Comparison of current classification systems.
    Neurology. 2018 Apr 13. pii: WNL.0000000000005476.
    PubMed     Text format     Abstract available


    March 2018
  14. ARENAZA-URQUIJO EM, Vemuri P
    Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies.
    Neurology. 2018 Mar 28. pii: WNL.0000000000005303.
    PubMed     Text format     Abstract available


    February 2018
  15. BENNETT DA, Gordon BA
    Alzheimer disease biomarkers and synucleinopathy.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005171.
    PubMed     Text format    


  16. MENDES A, Bertrand A, Lamari F, Colliot O, et al
    Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005165.
    PubMed     Text format     Abstract available


  17. BOTHA H, Mantyh WG, Graff-Radford J, Machulda MM, et al
    Tau-negative amnestic dementia masquerading as Alzheimer disease dementia.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005124.
    PubMed     Text format     Abstract available


  18. KNOPMAN DS
    Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005073.
    PubMed     Text format    


    January 2018
  19. AISEN PS
    Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:145.
    PubMed     Text format    


  20. PIAZZA F
    Reader response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:144-145.
    PubMed     Text format    


  21. KARAM C, Griggs RC
    Editors' note: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:144.
    PubMed     Text format    


  22. MATTSSON N, Smith R, Strandberg O, Palmqvist S, et al
    Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.
    Neurology. 2018 Jan 10. pii: WNL.0000000000004887.
    PubMed     Text format     Abstract available


    December 2017
  23. WILLIAMS DM, Karlsson IK, Pedersen NL, Hagg S, et al
    Circulating insulin-like growth factors and Alzheimer disease: A mendelian randomization study.
    Neurology. 2017 Dec 27. pii: WNL.0000000000004854.
    PubMed     Text format     Abstract available


  24. YASAR S, Whitmer R
    Statin use and risk of Alzheimer disease: A new view on an old relationship.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004837.
    PubMed     Text format    


  25. SINYAVSKAYA L, Gauthier S, Renoux C, Dell'Aniello S, et al
    Comparative effect of statins on the risk of incident Alzheimer disease.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004818.
    PubMed     Text format     Abstract available


  26. GROOT C, van Loenhoud AC, Barkhof F, van Berckel BNM, et al
    Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease.
    Neurology. 2017 Dec 13. pii: WNL.0000000000004802.
    PubMed     Text format     Abstract available


  27. GONNEAUD J, Arenaza-Urquijo EM, Mezenge F, Landeau B, et al
    Increased florbetapir binding in the temporal neocortex from age 20 to 60 years.
    Neurology. 2017;89:2438-2446.
    PubMed     Text format     Abstract available


    November 2017
  28. GROTHE MJ, Barthel H, Sepulcre J, Dyrba M, et al
    In vivo staging of regional amyloid deposition.
    Neurology. 2017;89:2031-2038.
    PubMed     Text format     Abstract available


  29. CORRIVEAU RA, Koroshetz WJ, Gladman JT, Jeon S, et al
    Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004717.
    PubMed     Text format     Abstract available


    October 2017
  30. GAUTHIER S, Ng KP, Pascoal TA, Mathotaarachchi S, et al
    Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017;89:1931.
    PubMed     Text format    


  31. LANDIN-ROMERO R, Kumfor F
    Letter re: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017;89:1931.
    PubMed     Text format    


  32. RISACHER SL, Anderson WH, Charil A, Castelluccio PF, et al
    Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.
    Neurology. 2017 Oct 25. pii: 10.1212/WNL.0000000000004670.
    PubMed     Text format     Abstract available


  33. WESTON PSJ, Poole T, Ryan NS, Nair A, et al
    Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.
    Neurology. 2017 Oct 25. pii: 10.1212/WNL.0000000000004667.
    PubMed     Text format     Abstract available


  34. FILIPPI M, Basaia S, Canu E, Imperiale F, et al
    Brain network connectivity differs in early-onset neurodegenerative dementia.
    Neurology. 2017;89:1764-1772.
    PubMed     Text format     Abstract available


  35. BRENOWITZ WD, Hubbard RA, Keene CD, Hawes SE, et al
    Mixed neuropathologies and associations with domain-specific cognitive decline.
    Neurology. 2017;89:1773-1781.
    PubMed     Text format     Abstract available


  36. KIEBOOM BCT, Licher S, Wolters FJ, Ikram MK, et al
    Serum magnesium is associated with the risk of dementia.
    Neurology. 2017;89:1716-1722.
    PubMed     Text format     Abstract available


  37. ROBERTS RO, Knopman DS, Syrjanen JA, Aakre JA, et al
    Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers.
    Neurology. 2017 Oct 13. pii: 10.1212/WNL.0000000000004652.
    PubMed     Text format     Abstract available


  38. GASBY D
    Alzheimer dementia's other victim: The spouse.
    Neurology. 2017 Oct 6. pii: 10.1212/WNL.0000000000004638.
    PubMed     Text format    


  39. WEINER MW, Crane PK, Montine TJ, Bennett DA, et al
    Traumatic brain injury may not increase the risk of Alzheimer disease.
    Neurology. 2017 Oct 4. pii: 10.1212/WNL.0000000000004608.
    PubMed     Text format     Abstract available


    September 2017
  40. MEDAGLIA JD, Huang W, Segarra S, Olm C, et al
    Brain network efficiency is influenced by the pathologic source of corticobasal syndrome.
    Neurology. 2017;89:1373-1381.
    PubMed     Text format     Abstract available


  41. CASALETTO KB, Elahi FM, Bettcher BM, Neuhaus J, et al
    Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.
    Neurology. 2017 Sep 22. pii: 10.1212/WNL.0000000000004569.
    PubMed     Text format     Abstract available


  42. NORTON DJ, Amariglio R, Protas H, Chen K, et al
    Subjective memory complaints in preclinical autosomal dominant Alzheimer disease.
    Neurology. 2017 Sep 6. pii: 10.1212/WNL.0000000000004533.
    PubMed     Text format     Abstract available


    August 2017
  43. MOSCONI L, Berti V, Quinn C, McHugh P, et al
    Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004425.
    PubMed     Text format     Abstract available



  44. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
    Neurology. 2017;89:980.
    PubMed     Text format    


  45. SMITH R, Scholl M, Widner H, van Westen D, et al
    In vivo retention of 18F-AV-1451 in corticobasal syndrome.
    Neurology. 2017;89:845-853.
    PubMed     Text format     Abstract available


  46. LI G, Mayer CL, Morelli D, Millard SP, et al
    Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004392.
    PubMed     Text format     Abstract available


    July 2017
  47. BENUSSI A, Di Lorenzo F, Dell'Era V, Cosseddu M, et al
    Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia.
    Neurology. 2017 Jul 26. pii: 10.1212/WNL.0000000000004232.
    PubMed     Text format     Abstract available


  48. DONADIO V, Incensi A, Rizzo G, Capellari S, et al
    A new potential biomarker for dementia with Lewy bodies: Skin nerve alpha-synuclein deposits.
    Neurology. 2017;89:318-326.
    PubMed     Text format     Abstract available


  49. LAFAILLE-MAGNAN ME, Poirier J, Etienne P, Tremblay-Mercier J, et al
    Odor identification as a biomarker of preclinical AD in older adults at risk.
    Neurology. 2017;89:327-335.
    PubMed     Text format     Abstract available


  50. SPIRA AP, Ju YS
    Self-reported sleep and Alzheimer disease CSF biomarkers: A wake-up call.
    Neurology. 2017 Jul 5. pii: 10.1212/WNL.0000000000004189.
    PubMed     Text format    


  51. MOFFAT SD
    Author response: Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2017;89:106.
    PubMed     Text format    


  52. LATTANZI S, Silvestrini M
    Letter re: Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2017;89:106.
    PubMed     Text format    


    June 2017
  53. ZHAN X
    Author response: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed     Text format    


  54. MENTE K
    Letter re: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed     Text format    


  55. BUCKLEY RF, Schultz AP, Hedden T, Papp KV, et al
    Functional network integrity presages cognitive decline in preclinical Alzheimer disease.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004059.
    PubMed     Text format     Abstract available


  56. ALCOLEA D, Vilaplana E, Suarez-Calvet M, Illan-Gala I, et al
    CSF sAPPbeta, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004088.
    PubMed     Text format     Abstract available


    May 2017
  57. GIANNINI LAA, Irwin DJ, McMillan CT, Ash S, et al
    Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia.
    Neurology. 2017 May 17. pii: 10.1212/WNL.0000000000004034.
    PubMed     Text format     Abstract available


  58. BOOTS EA, Schultz SA, Clark LR, Racine AM, et al
    BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003980.
    PubMed     Text format     Abstract available


    April 2017
  59. SCHULTZ SA, Boots EA, Darst BF, Zetterberg H, et al
    Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD.
    Neurology. 2017;88:1650-1658.
    PubMed     Text format     Abstract available


  60. NG KP, Pascoal TA, Mathotaarachchi S, Chung CO, et al
    Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017 Apr 12. pii: 10.1212/WNL.0000000000003916.
    PubMed     Text format     Abstract available


  61. PETERSEN RC, Thomas RG, Aisen PS, Mohs RC, et al
    Randomized controlled trials in mild cognitive impairment: Sources of variability.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003907.
    PubMed     Text format     Abstract available


  62. RELKIN NR, Thomas RG, Rissman RA, Brewer JB, et al
    A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003904.
    PubMed     Text format     Abstract available


    March 2017
  63. PAPP KV, Rentz DM, Mormino EC, Schultz AP, et al
    Cued memory decline in biomarker-defined preclinical Alzheimer disease.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003812.
    PubMed     Text format     Abstract available


    February 2017
  64. DAY GS, Lim TS, Hassenstab J, Goate AM, et al
    Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003770.
    PubMed     Text format     Abstract available


  65. TOSTO G, Bird TD, Tsuang D, Bennett DA, et al
    Polygenic risk scores in familial Alzheimer disease.
    Neurology. 2017 Feb 17. pii: 10.1212/WNL.0000000000003734.
    PubMed     Text format     Abstract available


  66. IMTIAZ B, Tuppurainen M, Rikkonen T, Kivipelto M, et al
    Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study.
    Neurology. 2017 Feb 15. pii: 10.1212/WNL.0000000000003696.
    PubMed     Text format     Abstract available


  67. CHEN J, Yu JT, Wojta K, Wang HF, et al
    Genome-wide association study identifies MAPT locus influencing human plasma tau levels.
    Neurology. 2017;88:669-676.
    PubMed     Text format     Abstract available


  68. FRANZMEIER N, Duering M, Weiner M, Dichgans M, et al
    Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003711.
    PubMed     Text format     Abstract available


  69. KREISL WC, Lawrence R, Page E, Teich AF, et al
    11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003693.
    PubMed     Text format    


    January 2017
  70. FEDOROVA TD, Seidelin LB, Knudsen K, Schacht AC, et al
    Decreased intestinal acetylcholinesterase in early Parkinson disease: An 11C-donepezil PET study.
    Neurology. 2017 Jan 18. pii: 10.1212/WNL.0000000000003633.
    PubMed     Text format     Abstract available


  71. THOMAS AJ, Attems J, Colloby SJ, O'Brien JT, et al
    Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.
    Neurology. 2017;88:276-283.
    PubMed     Text format     Abstract available


    December 2016
  72. ENNIS GE, An Y, Resnick SM, Ferrucci L, et al
    Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003537.
    PubMed     Text format     Abstract available


    November 2016
  73. MOKRY LE, Ross S, Morris JA, Manousaki D, et al
    Genetically decreased vitamin D and risk of Alzheimer disease.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003430.
    PubMed     Text format     Abstract available


  74. HOHMAN TJ, McLaren DG, Mormino EC, Gifford KA, et al
    Asymptomatic Alzheimer disease: Defining resilience.
    Neurology. 2016 Nov 4. pii: 10.1212/WNL.0000000000003397.
    PubMed     Text format     Abstract available


    October 2016
  75. KIKUCHI A, Okamura N, Hasegawa T, Harada R, et al
    In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.
    Neurology. 2016 Oct 28. pii: 10.1212/WNL.0000000000003375.
    PubMed     Text format     Abstract available


  76. ZHAN X, Stamova B, Jin LW, DeCarli C, et al
    Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2016 Oct 26. pii: 10.1212/WNL.0000000000003391.
    PubMed     Text format     Abstract available


  77. WESTON PS, Nicholas JM, Lehmann M, Ryan NS, et al
    Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003322.
    PubMed     Text format     Abstract available


  78. MATTIS PJ, Niethammer M, Sako W, Tang CC, et al
    Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003285.
    PubMed     Text format     Abstract available


    September 2016
  79. MATTSSON N, Zetterberg H, Janelidze S, Insel PS, et al
    Plasma tau in Alzheimer disease.
    Neurology. 2016 Sep 30. pii: 10.1212/WNL.0000000000003246.
    PubMed     Text format     Abstract available


    August 2016
  80. ROGALSKI E, Sridhar J, Rader B, Martersteck A, et al
    Aphasic variant of Alzheimer disease: Clinical, anatomic, and genetic features.
    Neurology. 2016 Aug 26. pii: 10.1212/WNL.0000000000003165.
    PubMed     Text format     Abstract available


  81. BURNHAM SC, Rowe CC, Baker D, Bush AI, et al
    Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up.
    Neurology. 2016 Aug 17. pii: 10.1212/WNL.0000000000003094.
    PubMed     Text format     Abstract available


    July 2016
  82. ZAREA A, Charbonnier C, Rovelet-Lecrux A, Nicolas G, et al
    Seizures in dominantly inherited Alzheimer disease.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003048.
    PubMed     Text format     Abstract available


  83. KNOPMAN DS, Jack CR Jr, Wiste HJ, Weigand SD, et al
    Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002979.
    PubMed     Text format     Abstract available


  84. KNICKMEYER RC, Ross ME
    Imaging and rare APOE alleles: Alzheimer disease as a developmental disorder.
    Neurology. 2016 Jul 13. pii: 10.1212/WNL.0000000000002956.
    PubMed     Text format    


  85. MORMINO EC, Sperling RA, Holmes AJ, Buckner RL, et al
    Polygenic risk of Alzheimer disease is associated with early- and late-life processes.
    Neurology. 2016 Jul 6. pii: 10.1212/WNL.0000000000002922.
    PubMed     Text format     Abstract available


  86. JACK CR JR, Bennett DA, Blennow K, Carrillo MC, et al
    A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.
    Neurology. 2016 Jul 1. pii: 10.1212/WNL.0000000000002923.
    PubMed     Text format     Abstract available


  87. FARFEL JM, Yu L, Buchman AS, Schneider JA, et al
    Relation of genomic variants for Alzheimer disease dementia to common neuropathologies.
    Neurology. 2016 Jul 1. pii: 10.1212/WNL.0000000000002909.
    PubMed     Text format     Abstract available


    June 2016
  88. CHO H, Choi JY, Hwang MS, Lee JH, et al
    Tau PET in Alzheimer disease and mild cognitive impairment.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002892.
    PubMed     Text format     Abstract available


  89. COLLOBY SJ, McKeith IG, Burn DJ, Wyper DJ, et al
    Cholinergic and perfusion brain networks in Parkinson disease dementia.
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002839.
    PubMed     Text format     Abstract available


    May 2016
  90. VOEVODSKAYA O, Sundgren PC, Strandberg O, Zetterberg H, et al
    Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
    Neurology. 2016;86:1754-61.
    PubMed     Text format     Abstract available


    April 2016
  91. VAN DEN BOSSCHE T, Sleegers K, Cuyvers E, Engelborghs S, et al
    Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002628.
    PubMed     Text format     Abstract available


  92. SWERDLOW RH
    Rare ABCA7 variants in Alzheimer disease: Guilt by association.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002630.
    PubMed     Text format    


  93. LE GUENNEC K, Nicolas G, Quenez O, Charbonnier C, et al
    ABCA7 rare variants and Alzheimer disease risk.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002627.
    PubMed     Text format     Abstract available


    March 2016
  94. LIM YY, Laws SM, Villemagne VL, Pietrzak RH, et al
    Abeta-related memory decline in APOE epsilon4 noncarriers: Implications for Alzheimer disease.
    Neurology. 2016 Mar 30. pii: 10.1212/WNL.0000000000002604.
    PubMed     Text format     Abstract available


  95. XIONG C, Jasielec MS, Weng H, Fagan AM, et al
    Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002593.
    PubMed     Text format     Abstract available


  96. GUTIERREZ J, Honig L, Elkind MS, Mohr JP, et al
    Brain arterial aging and its relationship to Alzheimer dementia.
    Neurology. 2016 Mar 16. pii: 10.1212/WNL.0000000000002590.
    PubMed     Text format     Abstract available


  97. WHITE LR, Edland SD, Hemmy LS, Montine KS, et al
    Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies.
    Neurology. 2016;86:1000-8.
    PubMed     Text format     Abstract available


  98. LANDAU SM, Horng A, Fero A, Jagust WJ, et al
    Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.
    Neurology. 2016 Mar 11. pii: 10.1212/WNL.0000000000002576.
    PubMed     Text format     Abstract available


    February 2016
  99. VEMURI P, Lesnick TG, Przybelski SA, Knopman DS, et al
    Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study.
    Neurology. 2016 Feb 24. pii: 10.1212/WNL.0000000000002490.
    PubMed     Text format     Abstract available


  100. GROSSMAN-KAHN R
    Reflections: Neurology and The Humanities. Charades with Alzheimer disease.
    Neurology. 2016;86:e73-4.
    PubMed     Text format    


  101. RANASINGHE KG, Rankin KP, Lobach IV, Kramer JH, et al
    Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage.
    Neurology. 2016;86:600-10.
    PubMed     Text format     Abstract available


    January 2016
  102. WELLINGTON H, Paterson RW, Portelius E, Tornqvist U, et al
    Increased CSF neurogranin concentration is specific to Alzheimer disease.
    Neurology. 2016 Jan 29. pii: 10.1212/WNL.0000000000002423.
    PubMed     Text format     Abstract available


  103. BEERI MS, Sonnen J
    Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression.
    Neurology. 2016 Jan 27. pii: 10.1212/WNL.0000000000002389.
    PubMed     Text format    


  104. DEL CAMPO N, Payoux P, Djilali A, Delrieu J, et al
    Relationship of regional brain beta-amyloid to gait speed.
    Neurology. 2016;86:36-43.
    PubMed     Text format     Abstract available


    December 2015

  105. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial.
    Neurology. 2015;85:2084.
    PubMed     Text format    


  106. TUFAN AN, Tufan F, Holmes C
    Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial.
    Neurology. 2015;85:2083-4.
    PubMed     Text format    


  107. HOLMES C
    Author Response.
    Neurology. 2015;85:2084.
    PubMed     Text format    


  108. BOYLE PA, Yu L, Nag S, Leurgans S, et al
    Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons.
    Neurology. 2015;85:1930-6.
    PubMed     Text format     Abstract available


    November 2015
  109. HENDERSON VW, Ala T, Sainani KL, Bernstein AL, et al
    Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial.
    Neurology. 2015 Nov 4. pii: 10.1212/WNL.0000000000002171.
    PubMed     Text format     Abstract available


    October 2015
  110. ZWAN MD, Rinne JO, Hasselbalch SG, Nordberg A, et al
    Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002081.
    PubMed     Text format     Abstract available


  111. AHMED RM, Latheef S, Bartley L, Irish M, et al
    Eating behavior in frontotemporal dementia: Peripheral hormones vs hypothalamic pathology.
    Neurology. 2015;85:1310-7.
    PubMed     Text format     Abstract available


    September 2015
  112. MORAN C, Beare R, Phan TG, Bruce DG, et al
    Type 2 diabetes mellitus and biomarkers of neurodegeneration.
    Neurology. 2015;85:1123-30.
    PubMed     Text format     Abstract available


  113. LANDY KM, Salmon DP, Galasko D, Filoteo JV, et al
    Motion discrimination in dementia with Lewy bodies and Alzheimer disease.
    Neurology. 2015 Sep 23. pii: 10.1212/WNL.0000000000002028.
    PubMed     Text format     Abstract available


  114. TURNER RS, Thomas RG, Craft S, van Dyck CH, et al
    A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.
    Neurology. 2015 Sep 11. pii: 10.1212/WNL.0000000000002035.
    PubMed     Text format     Abstract available


  115. PALMQVIST S, Zetterberg H, Mattsson N, Johansson P, et al
    Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000001991.
    PubMed     Text format     Abstract available


    August 2015
  116. KNOPMAN DS
    Is dominantly inherited Alzheimer disease a clone of sporadic Alzheimer disease?
    Neurology. 2015 Aug 5. pii: 10.1212/WNL.0000000000001897.
    PubMed     Text format    


  117. WANG F, Gordon BA, Ryman DC, Ma S, et al
    Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease.
    Neurology. 2015 Aug 5. pii: 10.1212/WNL.0000000000001903.
    PubMed     Text format     Abstract available


    July 2015
  118. CHILDRESS MD, Chen DT
    Art and Alzheimer dementia: A museum experience for patients may benefit medical students.
    Neurology. 2015 Jul 29. pii: 10.1212/WNL.0000000000001874.
    PubMed     Text format    


  119. FICHERA M, Bernasconi MP, Martinelli V, Comi G, et al
    Drawing in Alzheimer-type dementia.
    Neurology. 2015;85:386-7.
    PubMed     Text format    


  120. YONG KX, Rajdev K, Shakespeare TJ, Leff AP, et al
    Facilitating text reading in posterior cortical atrophy.
    Neurology. 2015;85:339-48.
    PubMed     Text format     Abstract available


  121. TIFRATENE K, Robert P, Metelkina A, Pradier C, et al
    Progression of mild cognitive impairment to dementia due to AD in clinical settings.
    Neurology. 2015;85:331-8.
    PubMed     Text format     Abstract available


  122. BREITNER JC
    Yet another "disconnect" between amyloid and Alzheimer disease?
    Neurology. 2015 Jul 24. pii: 10.1212/WNL.0000000000001871.
    PubMed     Text format    


  123. LIU E, Schmidt ME, Margolin R, Sperling R, et al
    Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
    Neurology. 2015 Jul 24. pii: 10.1212/WNL.0000000000001877.
    PubMed     Text format     Abstract available


  124. CASELLI RJ, Coon EA, Johansson L
    Midlife personality and risk of Alzheimer disease and distress: A 38-year follow-up.
    Neurology. 2015;85:298-9.
    PubMed     Text format    


  125. ALCOLEA D, Martinez-Lage P, Sanchez-Juan P, Olazaran J, et al
    Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
    Neurology. 2015 Jul 15. pii: 10.1212/WNL.0000000000001859.
    PubMed     Text format     Abstract available


  126. BARNES LL, Leurgans S, Aggarwal NT, Shah RC, et al
    Mixed pathology is more likely in black than white decedents with Alzheimer dementia.
    Neurology. 2015 Jul 15. pii: 10.1212/WNL.0000000000001834.
    PubMed     Text format     Abstract available


  127. TOLEDO JB, Bjerke M, Chen K, Rozycki M, et al
    Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.
    Neurology. 2015;85:144-53.
    PubMed     Text format     Abstract available


  128. AMARIGLIO RE, Mormino EC, Pietras AC, Marshall GA, et al
    Subjective cognitive concerns, amyloid-beta, and neurodegeneration in clinically normal elderly.
    Neurology. 2015;85:56-62.
    PubMed     Text format     Abstract available


    June 2015
  129. RAJAN KB, Wilson RS, Weuve J, Barnes LL, et al
    Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia.
    Neurology. 2015 Jun 24. pii: 10.1212/WNL.0000000000001774.
    PubMed     Text format     Abstract available


  130. GOETZL EJ, Boxer A, Schwartz JB, Abner EL, et al
    Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease.
    Neurology. 2015 Jun 10. pii: 10.1212/WNL.0000000000001702.
    PubMed     Text format     Abstract available


  131. GIDICSIN CM, Maye JE, Locascio JJ, Pepin LC, et al
    Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers.
    Neurology. 2015 Jun 10. pii: 10.1212/WNL.0000000000001704.
    PubMed     Text format     Abstract available


    May 2015
  132. MASSIMO L, Zee J, Xie SX, McMillan CT, et al
    Occupational attainment influences survival in autopsy-confirmed frontotemporal degeneration.
    Neurology. 2015;84:2070-5.
    PubMed     Text format     Abstract available


  133. OSORIO RS, Gumb T, Pirraglia E, Varga AW, et al
    Sleep-disordered breathing advances cognitive decline in the elderly.
    Neurology. 2015;84:1964-71.
    PubMed     Text format     Abstract available


    April 2015
  134. FOURNIER CN, Gearing M, Upadhyayula SR, Klein M, et al
    Head injury does not alter disease progression or neuropathologic outcomes in ALS.
    Neurology. 2015;84:1788-95.
    PubMed     Text format     Abstract available


  135. KIM SY, Karlawish J, Berkman BE
    Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
    Neurology. 2015;84:1488-94.
    PubMed     Text format     Abstract available


    March 2015
  136. WOLFSGRUBER S, Jessen F, Koppara A, Kleineidam L, et al
    Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.
    Neurology. 2015;84:1261-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: